T lymphocytes bearing the ab T cell receptor (TCR) but lacking CD4, CD8, and markers of natural killer (NK) cell differentiation are known as 'double-negative' (DN) T cells and have been described in both humans and rodent models. We and others have shown that DN T cells can act as regulatory T cells (Tregs) that are able to prevent allograft rejection, graft-versus-host disease, and autoimmune diabetes. In the last few years, new data have revealed evidence of DN Treg function in vivo in rodents and humans. Moreover, significant advances have been made in the mechanisms by which DN Tregs target antigen-specific T cells. One major limitation of the field is the lack of a specific marker that can be used to distinguish truly regulatory DN T cells (DN Tregs) from non-regulatory ones, and this is the central challenge in the coming years. Here, we review recent progress on the role of DN Tregs in transplantation and autoimmunity, and their mechanisms of action. We also provide some perspectives on how DN Tregs compare with Foxp3 1 Tregs.
Introduction
Double-negative (DN) T cells express the ab T cell receptor (TCR) but do not express CD4, CD8, or natural killer (NK) cell markers. They exist as a small (1%-5%) population of lymphocytes in the peripheral blood and lymphoid organs of normal rodents and humans. Peripheral T cells with a DN phenotype have been shown to be involved in immune regulation and tolerance as well as in host defense and inflammation. For example, whereas many studies have examined the regulatory function of DN T cells (detailed later), Crispin and colleagues described IL-17-secreting DN T cells derived from a CD8 + precursor in lupus patients (Crispin et al., 2008; Crispin and Tsokos, 2009) . In a similar vein, inflammatory DN T cells have been shown to confer protection against a variety of intracellular pathogens in murine models (Viret and Janeway, 2003; Cowley et al., 2005 Cowley et al., , 2010 Riol-Blanco et al., 2010) . Since the role of DN T cells in host defense and inflammation has been reviewed recently (D'Acquisto and Crompton, 2011) , this review will focus on recent advances in regulatory DN T cells (DN Tregs).
In 1989, Strober et al. (1989) reported that cloned 'natural suppressor' T cells from murine spleens that did not express CD4 or CD8 could suppress allogeneic mixed lymphocyte reactions, thus providing the first evidence that CD3 + , CD4 2 , and CD8 2 DN T cells may possess immune regulatory function. Since NK lineage markers were not examined in that study, one could not exclude the possibility of NK T cells being responsible for the observed suppression. A contemporaneous study showed that graft-versus-host disease (GVHD) in mice transplanted with bone marrow and splenocytes across a minor histocompatibility barrier was reduced when the donors were preimmunized with recipient splenocytes. The authors demonstrated that this reduction in GVHD was attributable to an ab TCR-expressing population that persisted despite depletion of CD4, CD8, and asialo-GM1 populations (Bruley-Rosset et al., 1990) . These early studies provided indirect evidence suggesting the DN T cells may act as Tregs, although their antigen-specificity and mechanisms of action were not determined. (Zhang et al., 2000) . We also described alloantigen-specific regulatory properties in the DN T cell compartment of lymphoproliferative (lpr) mice (Zhang et al., 2000; Ford et al., 2002) and non-transgenic mice (Zhang et al., 2000; Chen et al., 2003a) . Subsequent reports from various laboratories confirmed (Priatel et al., 2001) and extended these findings in other disease models in mice (Priatel et al., 2001; Ford et al., 2007; Ma et al., 2008; Duncan et al., 2010) , in rats (Hill et al., 2011) , and in humans (Fischer et al., 2005; Voelkl et al., 2011) . Many of the earlier studies on DN Tregs focused on the suppression of CD8 + T cell responses, but it has also been shown that DN Tregs can suppress CD4 + T cells (Ford et al., 2002; Chen et al., 2003a Chen et al., , 2005 Chen et al., , 2007 , B cells (Ma et al., 2008; Hillhouse et al., 2010) , NK cells (He et al., 2007) , and dendritic cells (DCs) (Gao et al., 2011) . In this review, we summarize some of the recent progress in our understanding of the biology of DN Tregs.
Ontogeny of DN Tregs
The origin of DN Tregs is not well understood. Some studies suggest that peripheral DN T cells can derive from the thymus (Egerton and Scollay, 1990; Mixter et al., 1999) but others support the notion that they develop in the periphery. During T cell development, thymocytes pass through a DN stage and then a CD4 + CD8 + stage prior to committing to a CD4 + or CD8 + lineage (Anderson and Jenkinson, 2001) . This observation led to the hypothesis that peripheral DN T cells may represent primitive ab T cells that bypassed the thymus entirely (Halder et al., 2001; Johansson and Lycke, 2003) , or alternatively, that they escaped further development into CD4 + or CD8 + T cells by traversing a rare alternative developmental pathway (Egerton and Scollay, 1990; Takahama et al., 1991) . A competing hypothesis is that peripheral DN T cells may arise de novo in the periphery from a CD4 + or CD8 + precursor that has downregulated its coreceptor (Schonrich et al., 1991; Merino et al., 1995; Mehal and Crispe, 1998) . We have shown that DN Tregs can develop in thymectomized, irradiated C57BL/6 mice which were reconstituted with either TCR transgenic 2C or C57BL/6 bone marrow expressing green fluorescent protein (Ford et al., 2006) . Interestingly, the regulatory function of the DN T cells in these mice was enhanced in comparison with DN T cells isolated from sham-thymectomized mice (Ford et al., 2006) . However, the frequency and total number of DN T cells in thymectomized mice are significantly reduced compared with sham-thymectomized controls (Ford et al., 2006) . These findings suggested that some DN Tregs can develop via a pathway that does not require a thymus. Furthermore, it has been reported that murine DN Tregs can be derived from CD4 + T cells by stimulating the latter with allogeneic bone marrow-derived DCs in the presence of IL-2 or IL-15 (Zhang et al., 2007) . The DN T cells of lpr mice are believed to have arisen from a peripheral CD8
+ precursor (Landolfi et al., 1993; Giese and Davidson, 1994; Maldonado et al., 1995) . Lymphoproliferation in lpr mice is greatly alleviated by neonatal thymectomy, including the accumulation of DN T cells (Steinberg et al., 1980; Wofsy et al., 1982 van Laethem et al. (2007) revealed that ab DN T cells could be generated in mice deficient in CD4, CD8, and MHC class I and II molecules, and that these cells could respond to non-MHC ligands, suggesting that the coreceptors function to limit the ab TCR repertoire to the subset capable of recognizing peptide -MHC complexes. It is possible that the DN T cells studied by van Laethem et al. (2007) are of a fundamentally different nature from DN Tregs as a result of an altered developmental pathway. To date, no specific marker of regulatory DN T cells has been identified. Neither murine (Zhang et al., 2007; Hillhouse et al., 2010; Gao et al., 2011) (Zhang et al., 2007) . Accumulation of DN T cells in the lpr mouse appears to require the transcription factor eomesodermin (Kinjyo et al., 2010) , and these cells are B220 + and have a central memory phenotype, being CD62L + and CD44 hi (Giese and Davidson, 1992) . How eomesodermin expression in these DN T cells relates to their regulatory properties, if at all, is unknown. Freshly isolated human DN Tregs express CD27, Fas, perforin, and low levels of CD28; in contrast, they largely lack expression of CD25 (Fischer et al., 2005) , although CD25 and CD45RO are upregulated after in vitro stimulation (Voelkl et al., 2011) . They also appear to have undergone extensive proliferation in vivo, as indicated by their low content of TRECs (Fischer et al., 2005) . These differences in surface marker expression may be a consequence of dissimilar activating stimuli and/or may reflect the differing developmental histories of the DN T cells, as described above. Identification of marker(s) that can be used to identify and isolate DN Tregs will certainly accelerate our understanding of their biology.
DN Tregs in the induction of donor-specific transplantation tolerance
The ability of DN Tregs to promote tolerance to MHC-mismatched allografts in an antigen-specific manner was first described in 2000 (Zhang et al., 2000) . The DN Tregs primarily examined in that study were derived from the 2C transgenic mouse, which has a TCR specific for the L d MHC class I molecule. (Zhang et al., 2000; Chen et al., 2003b) . Subsequent studies showed that DN Tregs from non-transgenic mice could also suppress syngeneic CD4 + T cells and inhibit the rejection of skin (Ford et al., 2002) and islet (Zhang et al., 2007) allografts as well as cardiac xenografts (Chen et al., 2003a) in a donor-specific manner. These studies revealed an essential role for (i) previous exposure of DN Tregs to cognate alloantigen in order to exert antigen-specific suppression and (ii) DN Treg-effector T cell contact and cytotoxicity mediated by TCR-MHC and Fas ligand-Fas interactions. These key conclusions laid the foundation for further work over the last several years that has expanded our understanding of DN Tregs. Mice with Fas (lpr) and Fas ligand (gld) mutations develop massive lymphadenopathy and accumulate a large number of DN T cells (Watanabe-Fukunaga et al., 1992; Takahashi et al., 1994) . Our data revealed that C57BL/6.lpr DN T cells, which express high levels of FasL, were capable of antigen-specifically promoting tolerance to skin allografts by killing syngeneic C57BL/6 Fas + CD4 + and CD8 + T cells in a FasL -Fas dependent manner (Ford et al., 2002) . In contrast, Hamad et al. (2003) showed that either lpr or gld DN T cells (the latter do not express functional Fas ligand) could suppress syngeneic T cells in a cell contact but Fas-independent fashion involving suppression of IL-2 and CD25 synthesis in the latter. These studies suggest that the DN compartment of lpr mice contains Tregs capable of antigen-specific immune regulation.
Recent studies of DN Tregs in disease models DN Tregs, GVHD, and bone marrow allograft rejection GVHD is a major complication of allogeneic bone marrow transplantation (BMT), and occurs when donor T cells present in the marrow graft are activated by recipient alloantigens (Shlomchik, 2007) . The result is damage to target organs including the gut, liver, skin, and lungs. While allogeneic CD4
+ and CD8 + T cells cause significant GVHD, infusion of allogeneic DN Tregs does not cause GVHD (He et al., 2007; our unpublished data).
Furthermore, we have shown that DN Tregs can prevent allogeneic CD8 + and CD4 + T cell-induced GVHD after BMT ; our unpublished data). In the study by Young et al. (2003a) 
, L d+ ) recipient mice were able to prevent GVHD caused by CD8 + T cells expressing the same anti-L d TCR.
More recently, we found that lpr DN T cells can exert suppression of GVHD mediated by CD4 + T cells in a haplotype mismatched GVHD model (our unpublished data). Extensive T cell depletion of donor bone marrow to prevent GVHD can increase the risk of relapse of hematopoietic malignancies, because of the loss of a beneficial graft-versus-leukemia (GVL) effect (Kolb, 2008) . Interestingly, we have also found, in a single MHC class I mismatched model, that DN T cells can kill allogeneic A20 lymphoma cells in vivo in the absence of GVHD . Hence, in murine models, DN Tregs appear to have the attractive property of being able to inhibit GVHD while mediating GVL. Additional studies are required to determine whether these observations can be extended to more clinically relevant settings characterized by additional MHC mismatches.
Another challenge with allogeneic BMT is the rejection of the bone marrow allograft by recipient NK cells. A recent publication by He et al. (2007) demonstrated that DN Tregs can promote marrow engraftment by inhibiting the NK-mediated rejection of donor bone marrow. This process required perforin expression by the DN Tregs, and the authors found that only DN Tregs capable of expressing this molecule could kill NK cells in vitro. Notably, direct NK cell killing in vivo by DN Tregs was not demonstrated in this study, but the effect of DN Tregs in promoting bone marrow allograft acceptance was comparable to the effect of NK cell depletion (using anti-asialo-GM1 antibody) on the same process. Adoptive transfer of DN Tregs promoted mixed chimerism in both semiallogeneic and fully MHC mismatched models of BMT, without causing GVHD. Taken together, all of these findings suggest that DN Tregs may be a useful adoptive therapy in clinical BMT.
Autoimmune diabetes
A number of studies have examined the control of autoimmunity by DN Tregs. Chiefly, these have been focused on murine models of autoimmune diabetes. Our group showed, in a TCR-transgenic system, DN Tregs specific for LCMV gp33 protein were able to prevent the development of insulitis and diabetes mellitus in mice expressing gp33 in pancreatic islets (Ford et al., 2007) . In this system, diabetes is induced by CD8 + T cells specific for gp33, which become activated and destroy insulin-producing cells upon injection of an agonistic anti-CD40 antibody. Adoptive transfer of pre-activated DN Tregs with the same antigen specifically and effectively prevented the onset of diabetes in animals treated with this antibody (Ford et al., 2007) . Two other groups (Dugas et al., 2010; Duncan et al., 2010; Hillhouse et al., 2010) have explored the ability of DN Tregs to inhibit the development of autoimmune diabetes. Duncan et al. (2010) observed that DN Tregs in non-obese diabetic (NOD) mice could prevent diabetes onset, but this was impaired owing to a progressive loss of DN Tregs with age. Prior to diabetes onset, young NOD mice show a transient expansion of DN T cells followed by a progressive decline in their numbers. NOD/ SCID mice, which lack autoreactive T cells, did not develop diabetes upon adoptive transfer of NOD DN T cells, indicating that this population is not diabetogenic. In contrast, transfer of NOD T cells resulted in diabetes. Cotransfer of NOD DN T cells and NOD T cells did not result in diabetes, indicating that the DN T cells could act as Tregs to inhibit insulitis caused by the NOD T cells. Two key strengths of this study were that (i) the NOD mouse is the model that most closely mimics the pathogenesis of human type 1 diabetes, and (ii) the DN Tregs studied in these animals were not expressing TCR transgenes. Hence, they provide a significant advance in our understanding of DN Treg function in a more clinically relevant context. Interestingly, however, the authors observed that the phenotype of some of the transferred DN T cells changed in the NOD/SCID recipients to become CD4 + Foxp3 2 IL-10-secreting cells. The alteration in phenotype might be explained by differences within the DN T cell pool of mice from the NOD background, or perhaps could reflect the influence of stimuli arising from the lymphopenic nature of the NOD/SCID host. It is an interesting phenomenon that, to our knowledge, has not been observed previously, and further investigation is required to determine whether it occurs in other settings. Indeed, a further fascinating aspect of the study by Duncan et al. (2010) was the role played by IL-10 in the function of the transferred cells, since neutralization of this cytokine abrogated their ability to prevent diabetes onset. This observation may indicate that the NOD environment triggers a different cytokine expression profile in DN Tregs from that seen in the aforementioned transplantation settings, which have been primarily performed on the C57BL/6 background. Alternatively, NOD DN Tregs may represent a cell type distinct from 2C or C57BL/6 DN Tregs.
The Lesage group (Hillhouse et al., 2010) shed additional light on this issue when they observed that 3A9 TCR transgenic NOD DN Tregs secrete much higher levels of IL-10 than 3A9 B10.Br DN Tregs. However, in their study IL-10 promoted apoptosis of 3A9 NOD DN Tregs. DN Tregs from both backgrounds could exert similar cytotoxic function against B cells expressing the hen egg lysozyme (HEL) cognate antigen in the context of the MHC class II molecule I-A k . Interestingly, cytotoxicity directed toward CD4 + or CD8 + T cells was not observed, leading the authors to speculate that the MHC-class II restriction imposed by the 3A9 TCR might redirect DN Treg cytotoxic function toward APCs. The authors also speculated that the secretion of IL-10 by NOD DN Tregs likely leads to an impairment in their survival in vivo, which ultimately leads to a reduction in their numbers and the onset of diabetes. In keeping with this explanation, we found that 2C DN Tregs are generally resistant to activation-induced cell death (Khan et al., 1999) but IL-10 increases the susceptibility of DN Tregs to this process (Marra et al., 2004) . Nevertheless, it seems difficult to reconcile this possibility with the observations of Duncan et al. (2010) , since the secretion of IL-10 by NOD DN Tregs was also central to their ability to suppress diabetes development. The explanation for this apparent contradiction may lie in the fact that Duncan et al.
(2010) employed adoptive transfer to NOD/SCID mice, which, being lymphopenic, may have provided survival stimuli that might retard the pro-apoptotic effects of IL-10 in this setting. Alternatively, there may be a critical ambient IL-10 concentration below which diabetes suppression occurs, but above which DN Treg apoptosis ensues. Lesage and co-workers (Dugas et al., 2010) also found that CD47 deficiency promoted diabetes onset in 3A9 TCR transgenic BALB.K mice engineered to express HEL under the control of the insulin promoter (i.e. restricted to the b cells of the islets of Langerhans). When CD47 was expressed, only about 20% of mice developed diabetes by 15 weeks of age; however, when CD47 was absent, diabetes onset was much earlier (6 weeks of age) and occurred in over 90% of mice. Intriguingly, these CD47-deficient mice showed no differences in CD4 ) have previously been implicated in the same phenomenon, and so it remains to be seen which of these population(s) are most relevant to the control of autoimmunity and whether these Tregs interact with each other in vivo.
Progress in human DN Tregs DN Tregs have been identified in humans (Fischer et al., 2005 ) and have been shown to have many of the same phenotypic properties as their murine counterparts, including secretion of interferon gamma (IFNg) and the acquisition of alloantigen from donor APCs followed by recognition and killing of activated CD8 + T cells specific for the same alloantigen -peptide complex (Fischer et al., 2005) . In a recent study, Voelkl et al. (2011) showed that human DN Tregs activated by allogeneic APCs or beads coated with anti-CD3 and anti-CD28 antibodies were capable of suppressing the proliferation of CD4 + and CD8 + T cells. Interestingly, this process was independent of FasL and perforin/granzyme, and the suppression was reversible in that, upon sorting of responder T cells from the culture and restimulation with fresh APCs, vigorous proliferation ensued. Furthermore, suppression could be exerted in the presence of anti-CD3/ anti-CD28-coated beads, indicating that human DN Tregs can exert suppression via an APC-independent pathway. As discussed below, this observation stands in contrast to the predominant in vivo suppressive mechanism described for CD4 
New insights into the mechanisms of DN Treg function
The past several years have seen a remarkable increase in our knowledge of how DN Tregs exert their regulatory effects. These are described in this section and summarized in Figure 1 . Notably, studies examining DN Treg function in widely differing model systems have revealed distinct phenotypic and mechanistic properties of these cells. for up to 7 days; furthermore, we found that the process of trogocytosis was antigen-specific in that DN Tregs only efficiently acquired L d from splenocytes pulsed with the high affinity 2C (Zhang et al., 2000; Fischer et al., 2005) , but the role of this cytokine in the regulatory function of these cells has not been explored until recently. Indeed, there is growing recognition that this prototypical inflammatory cytokine can have tolerance-promoting effects in transplantation and autoimmune disease (Brok et al., 1993; Yang et al., 1998; Gran et al., 2004; Wood et al., 2007) . Foxp3 + Tregs require IFNg to control allogeneic immune responses (Sawitzki et al., 2005; Wang et al., 2006; Wei et al., 2010) and, in parallel with these observations, IFNg is emerging as a key player in the function of DN Tregs. Using a rat cardiac allograft model, Hill et al. (2011) recently demonstrated that adoptive transfer of allogeneic bone marrowderived DCs in combination with the novel immunosuppressive agent LF15-0195 dosed daily for 10 days resulted in significant prolongation of allograft survival in comparison with LF15-0195 treatment alone. The spleens of rats receiving both treatments contained 3-fold higher concentrations of IFNg compared with those of rats receiving either treatment alone. The source of IFNg was determined to be DN Tregs which were found in close contact with the DCs in recipient spleens. DN Treg secretion of IFNg was augmented by EBI3 secretion by the DCs, and interference with this pathway using siRNA or neutralizing antibody resulted in decreased DN Treg IFNg secretion and augmented allograft rejection. These findings indicate that splenic DN Tregs, acting via IFNg, play an important role in solid organ allograft tolerance. Further studies will be required (Zhang and Thomson, 2011) to determine precisely how they use IFNg to achieve this effect. DN T cells from lpr mice, which have previously been shown to regulate syngeneic T cells (Ford et al., 2002; Hamad et al., 2003) , Double-negative regulatory T cells are nevertheless traditionally considered to be pathogenic in these mice and in humans with autoimmune lymphoproliferative syndrome (ALPS). We recently found, in a semiallogeneic BMT model, that lpr DN T cells can suppress GVHD mediated by syngeneic T cells without causing significant illness. Moreover, this process was dependent upon autocrine IFNg: lpr DN T cells that failed to secrete or respond to this cytokine were unable to upregulate surface FasL expression and could not suppress GVHD (our unpublished data). Interestingly, we also observed that IFNg-deficient lpr DN T cells were more impaired in suppression of CD4 + T cell proliferation in vitro than IFNg receptor-deficient lpr DN T cells, suggesting that there may be additional regulatory effects of DN T cell-secreted IFNg on other cells.
Interaction of DN Tregs with APCs
We have also recently shown that DN Tregs can cause downregulation of the costimulatory molecules CD80 and CD86 on DCs (Gao et al., 2011) . Using 2C TCR transgenic DN Tregs, we observed that L d -expressing lipopolysaccharide (LPS)-matured DCs that had been exposed to DN Tregs were unable to prime the proliferation of CD8 + T cells. This was due to a decrease in CD80 and CD86 expression on the DC surface, and this process required cytotoxic T lymphocyte antigen 4 (CTLA4) expression by DN Tregs, since CTLA4 2/2 DN Tregs were unable to downregulate the expression of these molecules on the DC surface. Furthermore, we found that alloantigen-expressing LPS-mature and immature DCs were susceptible to killing by DN Tregs, as were syngeneic DCs that had been pulsed with the 2C-specific peptide SIY (which can also be presented by the syngeneic MHC class I molecule K b ).
Additional studies by us (Ford McIntyre et al., 2010) and others (Ma et al., 2008; Hillhouse et al., 2010) have demonstrated that DN Tregs were able to kill both allogeneic and syngeneic B cells via a perforin-dependent pathway. These findings indicate that DN Tregs can suppress immune responses by exerting an effect on APCs, and hence significantly add to the repertoire of mechanisms by which DN Tregs can modulate allograft rejection. Another aspect of the relationship between DN Tregs and APCs is the finding that DN Tregs acquire regulatory potency through prior activation by exposure to cognate antigen. For example, in the case of DN Tregs expressing the 2C TCR, donor lymphocyte infusion (DLI) of L d+ splenocytes can facilitate acceptance of L d+ skin and cardiac allografts (Zhang et al., 2000; . We have also extended this observation to C57BL/6 DN Tregs accepting Lewis rat cardiac xenografts (Chen et al., 2003a) . In that study, DLI with rat splenocytes combined with a short course of in vivo depletion of CD4 + T cells led to permanent cardiac xenograft survival, whereas either treatment alone was insufficient. Subsequent studies showed that DLI significantly increased both total number of recipient DN Tregs and their suppressive function (Chen et al., 2005 (Chen et al., , 2007 . Furthermore, DLI-induced DN Tregs could suppress proliferation of xenoreactive CD4 + and CD8 + T cells and inhibit DC function (Chen et al., 2007) . In addition, xenoantigen-activated DN Tregs could kill xenoreactive B and T cells (Zhang et al., 2006) . We have also observed that a DLI of allogeneic splenocytes resulted in DN Treg expansion in lpr mice. These lpr DN Tregs, when adoptively transferred to B6 mice, could enhance the survival of skin grafts from the same donor strain as the DLI (but not from a third party) (Ford et al., 2002) . In these systems, exposure of the DN Tregs to allo-and xenoantigens resulted in the expansion of DN Tregs in the recipient, which were rendered capable of suppress other T cells responding to the same foreign antigens. Exposure to activating antigens either in vitro or in vivo also appears to be required for 3A9 (Hillhouse et al., 2010) (Shevach, 2009; Sakaguchi et al., 2010) . Neither rodent (Zhang et al., 2007; Hillhouse et al., 2010) (ii) do not produce IL-2, but require IL-2 and TCR stimulation for their activation and function (Zhang et al., 2000; Sakaguchi et al., 2008) ; (iii) can suppress syngeneic T cell proliferation in vitro and in vivo (Zhang et al., 2000; Young and Zhang, 2002; Ford McIntyre et al., 2008; Sakaguchi et al., 2008; Shevach, 2009) ; (iv) suppress in a cell contact-dependent fashion (Zhang et al., 2000; Sakaguchi et al., 2008) ; (v) express high levels of CTLA4 (Wing et al., 2008; Gao et al., 2011) , at least in the case of murine DN Tregs; (vi) can regulate costimulatory molecule expression on DCs in a CTLA4-dependent manner (Wing et al., 2008; Gao et al., 2011) ; (vii) can kill Ag-loaded DCs through the Fas/ FasL pathway (Gorbachev and Fairchild, 2010; Gao et al., 2011); and (ix) (Zhang et al., 2007; Hillhouse et al., 2010; Gao et al., 2011; Voelkl et al., 2011) . The suppression mediated by CD4 + Foxp3 + Tregs can be either Ag-specific or Ag-non-specific.
However, so far all studies on mouse, rat and human DN Tregs have shown that they suppress immune responses in an antigenspecific fashion both in vitro and in vivo. CD4 + CD25 + Tregs have been shown to be able to restrain the immature state of iDCs, but are incapable of suppressing LPS-induced DC maturation (Yamazaki et al., 2003; Fehervari and Sakaguchi, 2004; Onishi et al., 2008) . We showed that DN Tregs are potent suppressors of LPS-induced mDCs, through down-regulation of their costimulatory molecule expression as well as direct cytolysis (Gao et al., 2011 The origin and developmental regulation of DN Tregs are largely unknown. It is unclear whether DN Tregs arise from a peripheral mature T lymphocyte precursor or they represent a completely thymus-independent lineage. In any case, we and others (Bleesing et al., 2002) speculate that the massive accumulation of DN T cells in the lpr mouse probably represents a different process and that true DN Tregs develop in a distinct manner. Another possibility is that, as has been observed for Foxp3 + Tregs (Zhou et al., 2009; d'Hennezel et al., 2011) , significant phenotypic plasticity may exist within the DN Treg subset and not all DN T cells may be regulatory in all contexts. These hypotheses await further experimentation.
It is currently recognized that in order for Foxp3 + Tregs to be used as an adoptive cellular therapy for patients undergoing transplantation or with autoimmune diseases, more robust expansion methods will be required, and retention of a regulatory phenotype in vivo will need to be assured (Wieckiewicz et al., 2010) . For DN Tregs, the challenges are similar, and even greater. In addition to defining DN Treg-specific markers as described above, more clinically relevant animal models need to be developed, in which the function of DN Tregs and their phenotypes are carefully monitored in vivo and ex vivo. In parallel, expansion methods capable of generating large numbers of autologous DN Tregs will be required for further preclinical development. Despite these challenges, we believe that the potential of DN Tregs deserves further exploration because of their unique ability to confer antigen-specific tolerance, which suggests a potentially greater degree of safety than might be possible with adoptive Foxp3 + Treg therapy.
Conclusions DN Tregs are unique antigen-specific regulatory cells that can exert control over allograft rejection, GVHD, and autoimmune diseases. Although originally characterized in TCR-transgenic mice, emerging evidence suggests that non-transgenic DN Tregs and human DN Tregs have similar regulatory properties. Furthermore, DN Tregs can employ different mechanisms to regulate immune responses directed against allografts and autoantigens in both humans and rodents (Figure 1) . Although previous studies of DN Tregs were focused on their role in suppressing T cells, recent studies indicate that DN Tregs are also potent regulators of B cells, DCs, and NK cells. Specifically, the use of trogocytosis to regulate T cells with the same antigen specificity is a unique feature of DN Tregs that makes them an attractive potential cellular therapy for transplantation and autoimmunity. Likewise, an understanding of how DN Tregs use IFNg to regulate immune responses has also enhanced our knowledge of how these cells function in vivo. Hopefully, this property will inspire ongoing investigation in the coming years. 
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